Last reviewed · How we verify

salbutamol sulfate and ipratropium bromide

Universidade Federal do Rio Grande do Norte · Phase 1 active Small molecule

salbutamol sulfate and ipratropium bromide is a Small molecule drug developed by Universidade Federal do Rio Grande do Norte. It is currently in Phase 1 development.

At a glance

Generic namesalbutamol sulfate and ipratropium bromide
SponsorUniversidade Federal do Rio Grande do Norte
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about salbutamol sulfate and ipratropium bromide

What is salbutamol sulfate and ipratropium bromide?

salbutamol sulfate and ipratropium bromide is a Small molecule drug developed by Universidade Federal do Rio Grande do Norte.

Who makes salbutamol sulfate and ipratropium bromide?

salbutamol sulfate and ipratropium bromide is developed by Universidade Federal do Rio Grande do Norte (see full Universidade Federal do Rio Grande do Norte pipeline at /company/universidade-federal-do-rio-grande-do-norte).

What development phase is salbutamol sulfate and ipratropium bromide in?

salbutamol sulfate and ipratropium bromide is in Phase 1.

Related